SynthesisBMC neurology2025
Association between mitochondrial DNA copy number and the risk of Parkinson's disease: a meta-analysis and Mendelian randomization study.
Synthesis in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reduced Mitochondrial DNA Copy Number and Telomere Length in Essential Tremor Patients: Evidence from an Age- and Sex-Adjusted Cross-Sectional Case-Control Study.International journal of molecular sciences · 2026Article
- Association of mitochondrial genetic background with pS65-Ub in Lewy body disease.Acta neuropathologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson’s disease (PD) is a common neurodegenerative disorder characterized by both motor and non-motor symptoms, with mitochondrial dysfunction being a key pathological feature. Alterations in mitochondrial DNA copy number (mtDNA-CN) have been implicated in PD, but the relationship remains controversial. This study aimed to investigate the association between mtDNA-CN and PD through a meta-analysis and Mendelian randomization (MR) analysis to assess the potential causality.
methodsTo investigate the relationship between mtDNA-CN and PD, a comprehensive literature search was conducted across PubMed, Scopus, Web of Science, CNKI, and Wan Fang databases. Studies meeting predefined inclusion and exclusion criteria were selected, and a meta-analysis was performed to quantitatively synthesize the effect sizes. To further evaluate the potential causal association between mtDNA-CN and PD risk, MR analysis was conducted using genetic variants associated with mtDNA-CN as instrumental variables. Summary-level data were obtained from publicly available genome-wide association study (GWAS) datasets, including the IEU Open GWAS and FinnGen consortia. These analyses aimed to provide robust evidence regarding the potential causal role of mtDNA-CN in the pathophysiology of PD.
resultsThirteen studies meeting the inclusion criteria were included in the meta-analysis. A significant association was identified between reduced mtDNA-CN in cerebrospinal fluid and an increased risk of PD. However, no significant association was observed between mtDNA-CN levels in blood and PD risk. Additionally, although mtDNA deletion levels were slightly elevated in PD patients compared to controls, this difference did not reach statistical significance. MR analysis, based on aggregated data from the IEU Open GWAS and FinnGen datasets, did not support a causal relationship between mtDNA-CN and PD risk (p = 0.78). The robustness and consistency of the MR results were confirmed by Egger’s test and sensitivity analyses.
conclusionsThis study suggests that mtDNA-CN in cerebrospinal fluid holds potential clinical utility as a biomarker for PD. While further validation is needed, these findings contribute to a growing understanding of mitochondrial dysfunction in neurodegeneration and may offer new avenues for improving the diagnosis and management of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.